Description
RJW100 is a potent liver receptor homolog 1 (LRH-1, NR5A2) and steroidogenic factor-1 (SF-1, NR5A1) agonist with pEC50s of 6.6 and 7.5, respectively. RJW100 also causes strong activation of the miR-200c (miRNA-200c, microRNA-200c) promoter.
Product information
CAS Number: 1276664-20-0
Molecular Weight: 386.57
Formula: C28H34O
Chemical Name: (1R,3aR)-5-hexyl-4-phenyl-3a-(1-phenylethenyl)-1,2,3,3a,6,6a-hexahydropentalen-1-ol
Smiles: CCCCCCC1CC2[C@H](O)CC[C@@]2(C(=C)C2C=CC=CC=2)C=1C1C=CC=CC=1
InChiKey: ZFXMYHPLTQTTFW-XZSHQJGLSA-N
InChi: InChI=1S/C28H34O/c1-3-4-5-8-17-24-20-25-26(29)18-19-28(25,21(2)22-13-9-6-10-14-22)27(24)23-15-11-7-12-16-23/h6-7,9-16,25-26,29H,2-5,8,17-20H2,1H3/t25?,26-,28+/m1/s1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
RJW100 (compound 24-exo) treatment induces a significant dose-dependent increase in small/short heterodimer partner (SHP) transcripts beginning at 5 µM. RJW100 (compound 24-exo) clearly displaces the bound PIP2 phospholipid from SF-1 almost completely at 1 µM. Using hLRH-1 LBD alone that had not been complexed with any phospholipids, the result shows a clear dose-dependent shift in hLRH-1 LBD (ligand binding domain) native PAGE migration upon RJW100 (compound 24-exo; 0-100 µM) binding. RJW100 causes strong activation of the miR-200c promoter and exhibits strong ability to downregulate ZEB1 and ZEB2 proteins.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
